CrossBridge Bio Wins “Best Drug Developer” at 2025 World ADC Awards

CrossBridge Bio, a biopharmaceutical company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer more durable responses in patients, including those resistant to approved ADC therapies, today announced that it has been named the Winner of “Best Drug Developer” at the 2025 World ADC Awards.

“We’re honored to be recognized by the World ADC community. This award reflects our team’s relentless focus on designing ADCs that may meaningfully improve outcomes for patients facing difficult-to-treat cancers and change current clinical practice,” said Michael Torres, Ph.D., Chief Executive Officer of CrossBridge Bio. “Our dual-payload approach and branched linker chemistry are built to deliver deeper durable responses and to tackle resistance head-on, and we’re excited to advance our lead program toward the clinic.”

CrossBridge Bio’s proprietary platform integrates branched tripeptide linkers and dual-payload technology that enables the precise delivery of synergistic payload combinations within a single ADC molecule. The company’s lead asset, CBB-120, a TROP-2 targeted TOP1i/ATRi dual-payload ADC, has demonstrated compelling preclinical activity and was recently presented at the 2025 World ADC Conference, where it was the most attended non-plenary session in the event’s history.

“This award highlights the strength of our scientific approach and the dedication of our team,” said Dan Pereira, Ph.D., Chief Scientific Officer of CrossBridge Bio. “We’re developing ADCs that go beyond traditional designs—built to be more durable and address resistant tumors and to make a difference for patients who need new options. It’s exciting to see our work recognized on a global stage.”